Lv65
2020 积分 2024-03-08 加入
Discovery of an eIF4A Inhibitor with a Novel Mechanism of Action
19小时前
已完结
Unlocking Natural Potential: Antibody‐Drug Conjugates With Naturally Derived Payloads for Cancer Therapy
1天前
已完结
Design of PROTACs utilizing the E3 ligase GID4 for targeted protein degradation
1天前
已完结
Orthoallosteric EGFR‐TKIs: A New Paradigm in NSCLC Treatment Strategy Targeting the C797S Mutation
2天前
已完结
Overcoming E3 Ligase-Mediated Resistance: Development of Novel Hydrophobic Tagging-Based Degraders Targeting ALK Protein
3天前
已完结
The role of eIF4F-driven mRNA translation in regulating the tumour microenvironment
3天前
已完结
Dual-payload ADCs move into first oncology clinical trials
4天前
已完结
The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders
11天前
已完结
Journey of PROTAC: From Bench to Clinical Trial and Beyond
14天前
已完结
The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders
14天前
已完结
皖公网安备34019202002308
